• No results found

Human mesenchymal stromal cells : biological characterization and clinical application

N/A
N/A
Protected

Academic year: 2021

Share "Human mesenchymal stromal cells : biological characterization and clinical application"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Human mesenchymal stromal cells : biological characterization and clinical application

Bernardo, M.E.

Citation

Bernardo, M. E. (2010, March 4). Human mesenchymal stromal cells : biological characterization and clinical application. Retrieved from

https://hdl.handle.net/1887/15034

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded

from: https://hdl.handle.net/1887/15034

Note: To cite this publication please use the final published version (if applicable).

(2)

Stellingen behorende bij het proefschrift

Human Mesenchymal Stromal Cells: Biological Characterization and Clinical Application

1. Platelet lysate can replace fetal calf serum in the generation and ex vivo expansion of MSCs for cellular therapy (this thesis).

2. Human bone marrow-derived MSCs do not undergo malignant transformation after long term in vitro culture and do not exhibit mechanisms aimed at maintenance of telomere length (this thesis).

3. In patients given a T-cell depleted peripheral blood stem cell transplantation from an HLA-haploidentical relative, co-infusion of donor-derived MSCs with hematopoietic stem cells is safe and results in a reduction in the risk of graft failure (this thesis).

4. Infusion of ex-vivo expanded MSCs, regardless of the type of donor, is an effective and safe treatment for patients with steroid-resistant acute GvHD (this thesis).

5. The advent of regenerative medicine has provided clinicians with an effective armamentarium to cure several degenerative and immune-mediated conditions.

6. The efficacy of anti-Tumor Necrosis Factor monoclonal antibodies in the treatment of refractory fistulizing Crohn’s disease, despite being associated with great clinical expectations, is limited (Kamm MA, Ng SC. Clin Gastroenterol Hepatol 2008;6:7-10).

7. Children should not be excluded from the benefits of research (Lee L. J Pediatr Oncol Nurs. 1991;8:24-29).

8. When parents conceive a child with the nonexclusive aim of providing a donor for an existing child needing transplantation, there is no reason to criticise their choice (Burgio GR, Gluckman E, Locatelli F. Lancet. 2003;361:250-252).

9. We are always running for the thrill of it – Empire of the Sun 10. Transparency is the basis of any solid and imperishable relation.

11. Career development for women in medicine is a matter of making choices.

12. Poverty is the denial of all human rights – M. Yunus Maria Ester Bernardo

Leiden, 4 march 2010

Referenties

GERELATEERDE DOCUMENTEN

MSCs from bone marrow (BM) of 7 CD-patients (median age 32 years) were expanded ex vivo in the presence of 5% platelet lysate; cells were investigated for clonogenic

This work has been carried out in collaboration with the Departments of Pediatrics, Sub- Department Immunology, Haematology, Oncology, Bone Marrow Transplantation and

Also for this set of experiments, MSCs-FCS and MSCs-PL were chosen and tested for their genomic situation; in particular four of the eight BM donors were studied at baseline

MSCs from all donors were characterized by morphology, differentiation capacity and immune phenotype at different culture time points, namely P3, P6, P9, P12, P15 and later,

1 However, both primary (defined as lack of hematologic recovery or absence of donor chimerism) and secondary (defined as loss of donor chimerism after initial engraftment) 2

MSCs from bone marrow (BM) of 7 CD-patients (median age 32 years) were expanded ex vivo in the presence of 5% platelet lysate; cells were investigated for clonogenic

However, at present, no specific marker or combination of markers has been identified that specifically defines true MSCs and ex vivo expanded cells are currently stained with

Graft failure and delays in immune reconstitution reduce the overall survival of children undergoing haploidentical CD34 selected peripheral blood stem cell transplantation